New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 24, 2013
17:22 EDTCORTCorcept Therapeutics enters services agreement with Centric Health
Corcept Therapeutics disclosed in a regulatory filing that on May 21, the company entered into a services agreement with Centric Health Resources to provide the exclusive specialty pharmacy and patient services program for the company's drug Korlym, starting early in Q3. Under the terms of the agreement, subject to certain exceptions, Centric will act as the exclusive specialty pharmacy distributor of the product in the United States for the term of the agreement. The initial term of the agreement is a period of three years from the initiation of services under the agreement.
News For CORT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
16:15 EDTCORTCorcept says dose-finding portion of Phase 1/2 trial of Korlym combo completed
Corcept has completed the dose-finding portion of its Phase 1/2 trial of Korlym in combination with eribulin for the treatment of glucocorticoid receptor-positive TNBC. Recruitment of 20 patients to participate in the trial's efficacy phase is underway. These patients will receive 300 mg of Korlym daily, with eribulin at a dose of 1.1 mg/m2 administered intravenously. Results are expected in 2015. Although the dose-finding phase of the study was designed to assess only safety and tolerability, some preliminary efficacy data are available. Of the six patients in that phase who received the selected dose, three have TNBC. The only patient known to have GR-positive TNBC exhibited a partial response, defined as a 30 percent or greater reduction in tumor size, and has been on therapy for nine cycles. In contrast, the only patient known to have GR-negative TNBC suffered progression of disease. The third patient with TNBC began treatment recently. Her GR status and response to therapy is not yet known.
16:14 EDTCORTCorcept Therapeutics sees FY15 revenue $47M-$53M, consensus $49.54M
Subscribe for More Information
16:13 EDTCORTCorcept Therapeutics reports Q4 revenue $9.0M, consensus $8.93M
The company's estimated cash and cash equivalents were $24.2M at year-end.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use